LIDDS’ business model is to utilize LIDDS’ patented drug delivery technology to create more efficacious and safer treatments that result in greater value for patients, the company and its stakeholders. With a unique and well-positioned drug delivery technology and a strong pipeline, the attractiveness of LIDDS towards global partners with commercialization capacity will increase. The objective is to out-license the internally developed programs no later than Proof-of-Concept (PoC) in humans. Furthermore, LIDDS intends through solid scientific data and success to become a preferred drug delivery partner for global pharmaceutical companies interested in in-licensing the NanoZolid technology for their internal development programs. The business value for LIDDS will be through R&D milestone payments and royalties on commercial products. There is also an opportunity to extend IP life for out-of-patent drugs through reformulation with the NanoZolid technology.